A Novel Strategy to Develop Therapeutic Approaches to Prevent Proliferative Vitreoretinopathy
- 31 December 2011
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 179 (6), 2931-2940
- https://doi.org/10.1016/j.ajpath.2011.08.043
Abstract
No abstract availableKeywords
Funding Information
- Department of Defense (WB1XWH-10-1-0392)
- National Institutes of Health (EY012509)
- Allergan Horizon
This publication has 48 references indexed in Scilit:
- Pathological Signaling via Platelet-Derived Growth Factor Receptor α Involves Chronic Activation of Akt and Suppression of p53Molecular and Cellular Biology, 2011
- N-Acetylcysteine Suppresses Retinal Detachment in an Experimental Model of Proliferative VitreoretinopathyThe American Journal of Pathology, 2010
- Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathyExperimental Eye Research, 2010
- Growth Factors Outside the PDGF Family Drive Experimental PVRInvestigative Opthalmology & Visual Science, 2009
- PDGF receptors are activated in human epiretinal membranesExperimental Eye Research, 2009
- Growth Factors Outside of the Platelet-derived Growth Factor (PDGF) Family Employ Reactive Oxygen Species/Src Family Kinases to Activate PDGF Receptor α and Thereby Promote Proliferation and Survival of CellsPublished by Elsevier BV ,2009
- A Potential Role for PDGF-C in Experimental and Clinical Proliferative VitreoretinopathyPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2007
- Functional Characteristics of Connective Tissue Growth Factor on Vitreoretinal CellsDiabetes, 2007
- Vitreous leptin levels in retinal diseaseEye, 2005
- Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathyEye, 2002